FutureChem Co.,Ltd (KOSDAQ:220100)

Market Cap	390.89B
Revenue (ttm)	17.29B
Net Income (ttm)	-9.42B
Shares Out	22.10M
EPS (ttm)	-426.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	118,246
Average Volume	233,578
Open	17,740
Previous Close	17,690
Day's Range	17,500 - 18,270
52-Week Range	11,660 - 31,250
Beta	1.39
RSI	33.93
Earnings Date	May 12, 2025

About FutureChem Co.,Ltd

FutureChem Co.,Ltd engages in the research and development, production, and sale of radiopharmaceuticals in South Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson’s disease; Alzavue, a radiopharmaceutical for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303 and 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of athe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 220100

Financial Performance

In 2024, FutureChem Co.,Ltd's revenue was 17.29 billion, an increase of 23.81% compared to the previous year's 13.97 billion. Losses were -9.42 billion, 40.4% more than in 2023.